Physician profile
Gene Michael Roffers
NPI 1508186941
$1,917.50
in general payments reported to CMS, 2019-2025
18 companies · $73.64 in 2025
The $73.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $297 · 2021: $464 · 2022: $452 · 2023: $458 · 2025: $73.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.20 | 2021-2023 | Vraylar |
| Novo Nordisk INC | $296.20 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $266.41 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $131.03 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $106.14 | 2022-2023 | |
| Lilly USA, LLC | $97.72 | 2019-2023 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.31 | 2019-2022 | |
| Allergan, INC. | $92.06 | 2020 | |
| Pfizer INC. | $75.57 | 2019-2023 | |
| Exact Sciences Corporation | $51.12 | 2025 | The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $46.94 | 2019-2022 | |
| Amgen INC. | $35.44 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $29.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $26.14 | 2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.42 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.63 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.28 | 2025 | Capvaxive |
| Cashflow Solutions, LLC | $8.24 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Roffers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.